An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?

BMC Public Health

Table 3 Demographic, health, and health care use characteristics of COX-2 switchers and COX-2 stoppers in the first 100 days after discrediting of rofecoxib

Characteristic		COX-2 Switchers^a(N = 189) %	COX-2 Stoppers^a (N = 81) %	χ², df, p-value
Continuous Rofecoxib User		47	14	61.90, 1, < 0.0001
Urban Area		57	45	7.54, 1, 0.01
Able to Manage on Income		80	78	0.47, 1, 0.49
No Formal Education		72	73	0.03, 1, 0.87
Marital	Married/De facto	40	36
	Sep/Divorced	4	6	2.29, 1, 0.32
	Widowed/Single	56	58
BMI	Underweight	1	3
	Normal	44	48	0.02^b
	O/weight	55	49
Alcohol	Non-drinker	63	68
	Rarely/Low drinker	32	31	0.05^b
	Risky/High Risk	5	1
Smoker		4	5	0.77, 1, 0.38
Excellent/Very Good/Good General Health		63	59	0.60, 1, 0.44
Consulted Family Doctor ≥5 Visits		70	79	5.15, 1, 0.02
Hospital Doctor Visit in 12 months		19	26	3.36, 1, 0.07
Specialist Doctor Visit in 12 months		55	62	2.56, 1, 0.11
Conditions:
Ever Reported Arthritis		86	77	9.03, 1, 0.003
Hypertension		61	54	2.93, 1, 0.09
Depression		6	8	1.29, 1, 0.26
Anxiety/nervous		7	7	0.15, 1, 0.70
Asthma		9	11	0.24, 1, 0.62
Diabetes		14	11	0.93, 1, 0.33
Bronchitis/Emphysema		5	9	3.3, 1, 0.07
Heart Disease		21	27	2.16, 1, 0.14
Cancer		4	6	1.97, 1, 0.16

ISSN: 1471-2458